Connect with us

Technology

Hospital PMI® at 55.8%; June 2024 Hospital ISM® Report On Business®

Published

on

TEMPE, Ariz., July 5, 2024 /PRNewswire/ — Economic activity in the hospital subsector grew in June for the 10th consecutive month after contracting twice in the previous four-month period, with 35 consecutive months of growth prior to that, say the nation’s hospital supply executives in the latest Hospital ISM® Report On Business®.

The report was issued today by Nancy LeMaster, MBA, Chair of the Institute for Supply Management® (ISM®) Hospital Business Survey Committee: “The Hospital PMI® registered 55.8 percent in June, a 2.6-percentage point decrease from the May reading of 58.4 percent, indicating a 10th consecutive month of growth after a contraction in August. The Business Activity Index expanded for the 10th consecutive month. The New Orders Index expanded for the 10th straight month, and the Employment Index remained in growth territory. The Supplier Deliveries Index remained in expansion (which indicates slower delivery performance). The Case Mix Index expanded in June, registering 51 percent, a decrease of 0.5 percentage point compared to the previous month’s figure of 51.5 percent. The Days Payable Outstanding Index remained in expansion territory in June, registering 51.5 percent, down 5.5 percentage points from the 57 percent reported in May. The Technology Spend Index reading of 61.5 percent is an increase of 1 percentage point compared to the 60.5 percent recorded in May. The Touchless Orders Index was ‘unchanged’ in June, registering 50 percent, up 1.5 percentage points from the 48.5 percent reported in May.”

LeMaster continues, “The majority of Business Survey Committee respondents indicated that patient volumes in June were strong — just not as strong as in May. Some panelists commented that their facilities experienced a shift to more medical versus surgical patients, while others noted elevated levels of surgeries and outpatient volumes. The Employment Index continued to indicate growth, with respondents crediting successful recruitment efforts and a reduction in turnover. To preserve margins, hospitals continued to focus on (1) replacing agency labor with permanent staff to reduce labor costs and (2) reducing utilization and increasing standardization of supplies. Weather impacted supply deliveries in parts of the country, and the syringe shortage continues to be problematic.”

Hospital PMI® History

Month

Hospital PMI®

Month

Hospital PMI®

Jun 2024

55.8

Dec 2023

62.5

May 2024

58.4

Nov 2023

59.8

Apr 2024

53.5

Oct 2023

52.1

Mar 2024

52.3

Sep 2023

57.0

Feb 2024

56.6

Aug 2023

47.5

Jan 2024

61.5

Jul 2023

53.3

Average for 12 months – 55.9

High – 62.5

Low – 47.5

 

About This Report
The information compiled in this report is for the month of June 2024.

The Hospital PMI® was developed in collaboration with the Association for Health Care Resource & Materials Management (AHRMM), an association for the health care supply chain profession, and a professional membership group of the American Hospital Association (AHA).

The data presented herein is obtained from a survey of hospital supply executives based on information they have collected within their respective organizations. ISM® makes no representation, other than that stated within this release, regarding the individual company data collection procedures. The data should be compared to all other economic data sources when used in decision-making.

Data and Method of Presentation
The Hospital ISM® Report On Business® is based on data compiled from hospital purchasing and supply executives nationwide. Survey responses reflect the change, if any, in the current month compared to the previous month. For each of the indicators measured (Business Activity, New Orders, Employment, Supplier Deliveries, Inventories, Prices, Prices: Pharmaceuticals, Prices: Supplies, Backlog of Orders, Imports, Inventory Sentiment, Case Mix, Days Payable Outstanding, Technology Spend, and Touchless Orders), this report shows the percentage reporting each response and the diffusion index. Responses represent raw data and are never changed. Beginning in January 2021, the Report On Business® staff and consultants are gathering market information to better validate the Exports Index. Exports Index data are still being collected.

The Hospital PMI® is a composite index computed from the following, equally weighted indexes: Business Activity, New Orders, Employment and Supplier Deliveries. Diffusion indexes have the properties of leading indicators and are convenient summary measures showing the prevailing direction of change and the scope of change. A Hospital PMI® index reading above 50 percent indicates that the hospital sub-sector is generally expanding; below 50 percent indicates that it is generally declining. For the sub-indexes, except Supplier Deliveries, an index reading above 50 percent indicates that the sub-index is generally expanding; below 50 percent indicates that it is generally contracting. A Supplier Deliveries Index above 50 percent indicates slower deliveries and below 50 percent indicates faster deliveries.

The Hospital ISM® Report On Business® survey is sent out to the Hospital Business Survey Committee respondents the first part of each month. Respondents are asked to ONLY report on U.S. operations for the current month. ISM® receives survey responses throughout most of any given month, with the majority of respondents generally waiting until late in the month to submit responses to give the most accurate picture of current business activity. ISM® then compiles the report for release on the fifth business day of the following month.

ISM ROB Content
The Institute for Supply Management® (“ISM”) Report On Business® (Manufacturing, Services, and Hospital reports) (“ISM ROB”) contains information, text, files, images, video, sounds, musical works, works of authorship, applications, and any other materials or content (collectively, “Content”) of ISM (“ISM ROB Content”). ISM ROB Content is protected by copyright, trademark, trade secret, and other laws, and as between you and ISM, ISM owns and retains all rights in the ISM ROB Content. ISM hereby grants you a limited, revocable, nonsublicensable license to access and display on your individual device the ISM ROB Content (excluding any software code) solely for your personal, non-commercial use. The ISM ROB Content shall also contain Content of users and other ISM licensors. Except as provided herein or as explicitly allowed in writing by ISM, you shall not copy, download, stream, capture, reproduce, duplicate, archive, upload, modify, translate, publish, broadcast, transmit, retransmit, distribute, perform, display, sell, or otherwise use any ISM ROB Content.

Except as explicitly and expressly permitted by ISM, you are strictly prohibited from creating works or materials (including, but not limited to tables, charts, data streams, time-series variables, fonts, icons, link buttons, wallpaper, desktop themes, online postcards, montages, mashups and similar videos, greeting cards, and unlicensed merchandise) that derive from or are based on the ISM ROB Content. This prohibition applies regardless of whether the derivative works or materials are sold, bartered, or given away. You shall not either directly or through the use of any device, software, internet site, web-based service, or other means remove, alter, bypass, avoid, interfere with, or circumvent any copyright, trademark, or other proprietary notices marked on the Content or any digital rights management mechanism, device, or other content protection or access control measure associated with the Content including geo-filtering mechanisms. Without prior written authorization from ISM, you shall not build a business utilizing the Content, whether or not for profit.

You shall not create, recreate, distribute, incorporate in other work, or advertise an index of any portion of the Content unless you receive prior written authorization from ISM. Requests for permission to reproduce or distribute ISM ROB Content can be made by contacting Rose Marie Goupil in writing at: ISM Research, Institute for Supply Management, 309 W. Elliot Road, Suite 113, Tempe, AZ 85284-1556, or by emailing rgoupil@ismworld.org; Subject: Content Request.

ISM shall not have any liability, duty, or obligation for or relating to the ISM ROB Content or other information contained herein, any errors, inaccuracies, omissions or delays in providing any ISM ROB Content, or for any actions taken in reliance thereon. In no event shall ISM be liable for any special, incidental, or consequential damages, arising out of the use of the ISM ROB. Report On Business®, PMI®, Manufacturing PMI®, Services PMI®, and Hospital PMI® are registered trademarks and trademarks of Institute for Supply Management®. Institute for Supply Management® and ISM® are registered trademarks of Institute for Supply Management, Inc.

About Institute for Supply Management®
Institute for Supply Management® (ISM®) is the first and leading not-for-profit professional supply management organization worldwide. Its community of more than 50,000 in more than 100 countries manage about US$1 trillion in corporate and government supply chain procurement annually. Founded in 1915 by practitioners, ISM is committed to advancing the practice of supply management to drive value and competitive advantage for its members, contributing to a prosperous and sustainable world. ISM empowers and leads the profession through the ISM® Report On Business®, its highly-regarded certification and training programs, corporate services, events, and assessments. The ISM® Report On Business®, Manufacturing, Services, and Hospital, are three of the most reliable economic indicators available, providing guidance to supply management professionals, economists, analysts, and government and business leaders. For more information, please visit: www.ismworld.org.

The text version of the public Hospital ISM® Report On Business® is posted on ISM®’s website at www.ismrob.org on the fifth business day* of every month at 10:00 a.m. ET.

The next Hospital ISM® Report On Business® featuring July 2024 data will be released at 10:00 a.m. ET on Wednesday, August 7, 2024.

*Unless the New York Stock Exchange is closed.

Contact: 

Rose Marie Goupil

Report On Business® Analyst

ISM®, ROB/Program Manager

Tempe, Arizona

+1 480.752.6276, ext. 3005

Email: rgoupil@ismworld.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/hospital-pmi-at-55-8-june-2024-hospital-ism-report-on-business-302189179.html

SOURCE Institute for Supply Management

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Nanalysis Announces Board Transition and Appointment of Three New Directors

Published

on

By

CALGARY, AB, May 1, 2026 /CNW/ – Nanalysis Scientific Corp. (the “Company”, TSXV: NSCI, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology for industrial and research applications, is pleased to announce the appointment of Jonathan Ladd, Werner Maas, and Steve Feick to its Board of Directors effective May 1, 2026.

Mr. Ladd is an experienced technology executive and former Chief Executive Officer of NovAtel Inc., a Nasdaq-listed GPS technology company acquired by Hexagon AB. He has a track record of scaling global technology businesses and brings extensive experience in capital markets, corporate governance, and strategic execution within advanced technology companies. He currently serves on the following boards: Takemetoit Inc., AgriRobot, Litus Inc., and is an advisor at Tall Grass Ventures. Mr. Ladd earned a bachelor’s degree with distinction in engineering and is a member of Tau Beta Pi National Engineering Honor Society.

Dr. Maas is a senior executive in the analytical instrumentation sector, having previously served as President of Bruker BioSpin Corporation and currently serving as Chief Executive Officer of Hudson Lab Automation. He brings deep expertise in nuclear magnetic resonance (NMR) technologies, as well as global sales, marketing, and commercialization of scientific instrumentation. Dr. Maas holds a Ph.D. in Chemistry from Radboud University in The Netherlands, as well as several executive management designations from the MIT Sloan School of Management.

Mr. Feick is President of Manvest Inc., part of the Mancal Group. He has a track record of developing and growing a portfolio of investments in agriculture, finance, supply chain, infrastructure technology, energy efficiency, and data analytics. As a former entrepreneur, he ensures that his operational and investor experience elevates the growth of the portfolio. He is an experienced investor and brings expertise in capital allocation, governance, and long-term strategic planning across private and public market investments. Mr. Feick holds a Bachelor of Science degree in Chemical Engineering from Queen’s University.

In connection with these appointments, Martin Burian and Jennifer Stubbs will be stepping down from the Board of Directors, effective May 1, 2026. The Company thanks Mr. Burian and Ms. Stubbs for their contributions and service and wishes them continued success in their future endeavours.

“On behalf of the Board, I would like to thank Martin and Jennifer for their contributions to Nanalysis and dedicated service to the Company and wish them continued success in their future endeavours.” said Sean Krakiwsky, Chief Executive Officer. “We are pleased to welcome Jonathan, Werner, and Steve. Their collective experience across instrumentation, global commercialization, and capital allocation will support the Company as we focus on scaling our core NMR platform and executing on our services growth strategy.”

About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1)

Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-announces-board-transition-and-appointment-of-three-new-directors-302759750.html

SOURCE Nanalysis Scientific Corp.

Continue Reading

Technology

PCIS Emerges as Leading Risk and Claims Provider in Mid-Atlantic with Three Major Wins

Published

on

By

SEPTA, City of Baltimore, and Maryland Department of Transportation MTA adopt ClaimsVISION to modernize risk and claims operations

NEW YORK, May 1, 2026 /PRNewswire-PRWeb/ — PCIS, a leading provider of Risk & Claims Management Information System (RMIS), today announced a series of new and expanded client engagements across the Mid-Atlantic region, further solidifying its position as a trusted partner for transit agencies and public sector organizations.

“The biggest barrier to innovation in the public sector isn’t a lack of tools—it’s the weight of legacy data environments that were never built for real-time intelligence. You can’t layer AI on top of fragmented, batch-driven systems and expect results.

The Southeastern Pennsylvania Transportation Authority (SEPTA) has selected PCIS ClaimsVISION RMIS to enhance its risk management capabilities and support more efficient claims oversight. The City of Baltimore has chosen ClaimsVISION Claims and RMIS to modernize its claims administration and enterprise risk management operations. In addition, the Maryland Department of Transportation Maryland Transit Administration (MDOT MTA) has entered into a new five-year agreement with PCIS, extending a long-standing partnership and continuing its use of the ClaimsVISION platform.

These engagements reflect a broader trend among public entities seeking modern, configurable platforms to improve visibility, streamline workflows, and strengthen compliance across increasingly complex risk environments.

“The biggest barrier to innovation in the public sector isn’t a lack of tools—it’s the weight of legacy data environments that were never built for real-time intelligence. You can’t layer AI on top of fragmented, batch-driven systems and expect results. Organizations like SEPTA and Baltimore are rethinking the foundation—moving toward continuous, streaming data models that actually enable AI to deliver value”, said Michael Loizou, CSO of PCIS.

Across these implementations, PCIS will deliver a unified platform designed to:

Centralize claims and risk data for improved decision-makingEnhance BI and intelligent analytics capabilitiesStreamline workflows and reduce manual processesSupport regulatory compliance and audit readinessEnable scalable, configurable solutions tailored to public sector needs

The continued expansion of PCIS within the Mid-Atlantic region underscores the company’s growing presence among transit agencies and public entities seeking proven, purpose-built risk and claims management solutions.

Media Contact

Helene Quinn, PCIS, 1 2124051625, hquinn@pcisvision.com, www.pcisvision.com

View original content to download multimedia:https://www.prweb.com/releases/pcis-emerges-as-leading-risk-and-claims-provider-in-mid-atlantic-with-three-major-wins-302759785.html

SOURCE PCIS

Continue Reading

Technology

Private Equity’s AI Moment: The Greatest Value Lever in Decades — and the Hardest to Pull

Published

on

By

The following article is authored by Neil Dhar, Senior Vice President, IBM Consulting Americas

ARMONK, N.Y., May 1, 2026 /PRNewswire/ — Next week at Think 2026, we’ll outline the forces shaping the Enterprise AI Race, forces that apply with particular urgency to private equity. The organizations gaining ground today are not the ones betting on a single model. They are the ones redesigning how their businesses operate, building hybrid architectures that give them control, and deploying AI in ways that orchestrate value that compounds over time. 

The private equity industry understands this better than most. The days of pilots and promises are over, and the demand for hard proof (a.k.a. ROI) has begun. Is your revenue accelerating? Can you drive efficiency and profitability at the same time? What does long-term growth look like? These are the questions sitting across the table at every board meeting and investment committee, and the pressure is only intensifying.  

This pressure has forced major PE firms to move aggressively to formalize their AI strategies, including exploring joint ventures with leading LLM companies. They’re making a calculated bet on AI as the most powerful value‑creation lever the industry has seen in its history, and they recognize that the window to move is now. 

The logic is unmistakable. PE firms don’t run single businesses, they run portfolios. Which means AI playbooks that work don’t just transform one company; they compound across ten, twenty, fifty, hundreds. A workflow reinvented once becomes a repeatable asset. A governance framework built once becomes portfolio infrastructure. That multiplier effect is native to how PE creates value, and it’s what makes the intersection of private equity and enterprise AI one of the most consequential arenas in business right now. 

The bet is a no-brainer. Execution is where it gets hard.  

Here’s what we know to be true: competitive advantage won’t come from betting on a single LLM. It will come from building AI tailored to your business, shifting to a hybrid strategy that combines custom models, foundation models, and smaller specialized models, all grounded in an architecture that connects your data, your workflows, and your intelligence. In private equity, where the same playbook has to work across an entire portfolio, that distinction isn’t academic. It’s the difference between value that compounds and value that stalls. 

We know this because we lived it. We turned our own operations into the proving ground, analyzing nearly 400 operational workflows and deploying AI solutions across more than 100 so far, coupled with AI governance and enablement.

The result was $4.5B in productivity gains from AI, hybrid cloud, automation and consulting expertise, and proof of what works.

We then took that proof and productized those validated workflows into IBM Enterprise Advantage, a first-of-its-kind asset-based consulting service that enables clients to build and operate their own tailored internal AI platform at scale.

With digital workers, prebuilt tools, and native governance, clients have a headstart rather than a blank slate. And because it’s multi-model, they retain the freedom to shift as technology evolves. For private equity, that flexibility determines whether a company is an asset or a liability at exit. 

We’re bringing this same approach to private equity-backed companies, where the defining question is what changed and can you prove it.

A major U.S. telecommunications provider is deploying digital workers and prebuilt AI tools from Enterprise Advantage to accelerate the migration of more than 150 critical applications, delivering measurable savings within two quarters.Working with a leading insurance administrator, IBM is using agentic AI to overhaul end-to-end claims processing, a function where a single claim can involve dozens of tightly regulated steps across multiple systems. AI agents now read and structure claim documents, perform compliance checks, assess eligibility, and route cases automatically, resulting in faster cycle times, fewer bottlenecks, and an operating model built to scale. 

What private equity does here will ripple far beyond its own portfolios. When PE-backed companies deploy production-ready AI across the business, they reset competitive expectations for entire industries, forcing every competitor to respond. That is the Enterprise AI Race playing out in real time.

The choices made today will define portfolio performance for the next decade. Move too slowly and you’re handing the advantage to every competitor who didn’t. Move without discipline and you’re betting the portfolio on a foundation that hasn’t been proven. The firms that win will be the ones who understood that distinction early enough to do something about it.

About IBM 

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media contact: 

IBM
Lily O’Brien
lilyobrien@ibm.com

SOURCE IBM

Continue Reading

Trending